Activision Blizzard Inc. (NASDAQ: ATVI) Reiterated Buy with $18 target at Argus.
Air Products & Chemicals Inc. (NYSE: APD) Reiterated Buy at BofA/ML.
Chimera Investment Corporation (NYSE: CIM) Cut to Sell at Wunderlich.
Dell Inc. (NASDAQ: DELL) Maintained Underperform at Credit Suisse; Reiterated Buy with $22 target at Argus.
Dick’s Sporting Goods Inc. (NYSE: DKS) Raised to Conviction Buy List at Goldman Sachs.
Gentiva Health Services (NASDAQ: GTIV) named Bear of the Day at Zacks.
Geron Corporation (NASDAQ: GERN) Cut to Neutral at JPMorgan.
Plains All American Pipeline, L.P. (NYSE: PAA) named Value stock of the day at Zacks.
Research in Motion Ltd. (NASDAQ: RIMM) Raised to Neutral from Sell at Goldman Sachs.
Sunoco Logistics, LP (NYSE: SXL) named Bull of the Day at Zacks.
TIBCO Software Inc. (NASDAQ: TIBX) Started as Market Perform at BMO Capital; Started as Market Outperform at JMP Securities.

Your email address

subscribe

terms and conditions

JON C. OGG

Alcatel-Lucent (NYSE: ALU) was up the most of all networking stocks this year, so it can’t be too shocking to see it whacked yet again.  Shares are down over 12% at $3.11.

Bank of America Corporation (NYSE: BAC) is no surprise and the news is AIG and the bank’s risks to future suits etc… Shares are down 9.3% at $7.42.

Cheniere Energy, Inc. (AMEX: LNG) is one of the still very speculative players and the precipitous drop in nat-gas is not helping a leveraged player today.  Shares are down a whopping 18% at $6.40.

Crude Carriers Corp. (NYSE: CRU) is following is big leg down from Friday and shares are down 15% at $7.01.

DR Horton Inc. (NYSE: DHI) is down 5.1% at $9.87 and the 52-week low is $9.73. When credit gets tighter, how great is it for homebuilders in an already-weak market?  Ditto for all of its peers.

Ford Motor Company (NYSE: F) is down for the risk to U.S. auto sales as the buyers who rely upon credit can easily put off car buying.  Ford is down 6.5% at $10.13… risk of double-digits again? That was a 52-week low today.  General Motors Company (NYSE: GM) is now down 5.5% at $24.86 and shares came within two cents of the post-IPO lows of $24.49 already today.

Freescale Semiconductor Inc. (NYSE: FSL) may be highly diversified, but that is not helping.  It was not exactly on the most solid footing when the IPO came about and shares are down another 9.5% at $10.73 after having hit a new 52-week low of $9.57.

Geron Corporation (NASDAQ: GERN) has no news as the leader in stem cell research, but StemCells Inc. (NASDAQ: STEM) is down almost 17% at $2.16.  Geron shares are down 9.5% at $2.68 today.

Imperial Sugar Co. (NASDAQ: IPSU) lost over half its value on Friday after management just lost all credibility with its discussion about a loss.  The company had just been out pitching its new “alternative sweetener model” rather than just sugar but the damage is extreme now.  Shares are down another 14% at $8.09.

Iridium Communications Inc. (NASDAQ: IRDM) is suffering with the international growth scene now.  How many people need satellite phones if the purses get tightened too much?  Shares are down almost 7% at $7.38.

Nordstrom Inc. (NYSE: JWN) is probably seeing a few less up-sales this week and shares are trading down 5.5% at $41.87 on the day.  That is still well above $the $28.44 low of the last year.

Sirius XM Radio Inc. (NASDAQ: SIRI) is getting unusually punished due to the risks to auto sales being the first economic spot hit.  Who cares if Howard Stern is there or not on a day like today?  Shares are down 7% at $1.68.

Sprint Nextel Corporation (NYSE: S) is down yet again and down another 7.8% at $3.43 in active trading.  We said the worst was not over there just last week and stick by that statement.  It will take a bull market to save Sprint.

VirnetX Holding Corporation (AMEX: VHC) is the patent player that sues companies for royalties. How relevant it is when its “patent partners” are getting whacked so hard is up to.  The market vote is that the model is not relevant as shares are down 15% at $18.71 this morning.  Keep in mind that the 52-week range is $5.65 to $41.77.  Rambus Inc. (NASDAQ: RMBS) is another “patent licensing operation” that is suffering, with shares down 8% at $10.64 and the stock hit a 52-week high of $10.15 today.

Another day of selling as the great flush continues… The good news is only that the bad news is bad enough and it has been bad enough that at some point you have to expect bargain buyers to surface.

JON C. OGG

We included the research summaries, included price action data, and added in color if applicable.  At the end we also have three macro-calls which are bonus calls that are not really equity calls but which need to be considered by investors.

The Active Network, Inc. (NYSE: ACTV) is a strange company and one which we figured would be given ratings like Neutral, Hold, Market Perform, and the like as it is an online community that offers application services technology and marketing access to community service and sports organizations.  It has a $1 billion market cap as well. Shares closed at $18.89 on Friday, up from $18.01 the week before and versus a $15.00 IPO price which has never been breached.  Still, the analyst community was entirely positive as the post-IPO quiet period came to an end:

• Citigroup- Buy
• RBC- Outperform
• Stifel Nicolaus- Buy
• ThinkEquity- Buy

Apple Inc. (NASDAQ: AAPL) may not seem like much on the surface because it was a reiterated Buy and the target was raised only $15 to $500 for the stock, but this call from Canaccord Genuity did actually move the meter.  Apple shares closed up 0.7% at $359.71 on a day that the NASDAQ closed down 0.45%.  What is amazing is that this was actually the highest closing price since the $360.00 close on March 4 and it was about ten days ahead of the earnings report.

Estee Lauder Companies Inc. (NYSE: EL) is being dubbed “The Misnomer Call of the Week” after Credit Suisse started coverage with a “Neutral” rating and gave a $95.00 price target objective.  By our take, Neutral implies no direction or no real value for the stock to move either way.  What makes this one dubious is that the price was already just above $105 going into the call.  This was really a “Stealth Sell Rating” by our take.  The Thomson Reuters consensus price target is $105.29 now, which implies that the rest of the analysts on average are “Neutral.”

Geron Corporation (NASDAQ: GERN) was given a key analyst call and shares were up almost 10% at $4.39 on Friday.  J.P.Morgan started coverage with an “Overweight” rating for the stem cell leader and assigned a $6.00 price target. The call was timed almost perfectly as all stem cell shares rallied on reports that Swedish doctors were able to use stem cells to replace the trachea of a patient suffering from advanced cancer.  Sometimes it is better to be lucky than good, but the call had to impact the overall group as well.

Google Inc. (NASDAQ: GOOG) took a downgrade on Friday from Morgan Stanley, where the rating was cut to Equal-Weight from Overweight and the target was cut to $600 from $645 in the call.  With this being 4 trading days before earnings, we could not help but notice the impact.  Google was started with a Buy rating at Collins Stewart earlier in the week and it was given that street-high $800 target from Canaccord Genuity just the week before.

Netflix, Inc. (NASDAQ: NFLX) saw a major jump after the entertainment research team at Bank of America Merrill Lynch reiterated its Buy rating.  What mattered was that it was a street-high price target objective at $325.00 as the bogey.  We already opined that calling a top or predicting when this major run ends is nearly impossible, but we would caution one thing: that is only 10% left in implied upside to the highest analyst target.  After the run this one has seen, its earnings or another event could easily take out 10% of the share price.

Apple Inc. (NASDAQ: AAPL) Reiterated Buy and raised target to $500 at Canaccord Genuity.
Avon Products Inc. (NYSE: AVP) Started as Neutral with $30 target at Credit Suisse.
Banco Santander, S.A. (NYSE: STD) Cut to Underperform at Bernstein.
Estee Lauder Companies Inc. (NYSE: EL) Started as Neutral with $95 target at Credit Suisse.
Geron Corporation (NASDAQ: GERN) Started as Overweight at JPMorgan.
Google Inc. (NASDAQ: GOOG) Cut to Equal-weight at Morgan Stanley.
Hudson City Bancorp (NASDAQ: HCBK) Cut to Underperform as Bear of the Day at Zacks.
Integra LifeSciences Holdings Corporation (NASDAQ: IART) Started as Neutral at BofA/ML.
Research In Motion Ltd. (NASDAQ: RIMM) Maintained Hold and $35 target at Canaccord Genuity.
Standard Motor Products (NYSE: SMP) Maintained Outperform as Bull of the Day at Zacks.
The TJX Companies, Inc. (NYSE: TJX) Raised to Hold at Citigroup.
Tractor Supply Company (NASDAQ: TSCO) Reiterated Buy and raised target to $80 at BofA/ML.
Visa Inc. (NYSE: V) Reiterated Buy and raised target to $100 at Argus.
Western Refining Inc. (NYSE: WNR) Reiterated Buy as Value at Zacks.

You are invited to join our free daily email distribution list to hear more about analyst upgrades and downgrades, top day trader and active trader alerts, dividend trends, news on Buffett and other investment gurus, IPOs, secondary offerings, private equity, and more.

JON C. OGG

Our screen was looking for roughly 50% upside or more to the consensus analyst price target at Thomson Reuters.  We also screened out extreme small cap names and those which are too thin in volume.  We came up Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), Dendreon Corporation (NASDAQ: DNDN), Geron Corporation (NASDAQ: GERN), Halozyme Therapeutics, Inc. (NASDAQ: HALO) and VIVUS Inc. (NASDAQ: VVUS).  There were actually enough in the $200 million to $1 billion range that we’ll probably have another list tomorrow.  Thomson Reuters has a consensus price target of $17.94 but a median price target of $15.00.  The analyst field is also very mixed here and the coverage looks a bit stale by our count.  The lower target still implies upside of more than 55%.

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is fresh off news that it won a $10 milestone payment from Takeda in Japan on part of its gene silencing drug collaboration.  Alnylam transferred its RNA technology and it stands to win up to $1 billion ($140 million or so collected so far) if all milestones and targets get reached.  With shares at $9.65, its 52-week trading range is $8.79 to $17.59 and its market cap is almost $410 million.

Dendreon Corporation (NASDAQ: DNDN) was surprising to see on the list of implied upside targets despite its Provenge which has been approved for prostate cancer.  Shares are already up big from before its approval, but they are also considerably from highs.  The revenue stage has not yet gone into full tilt as production is being ramped up through 2011 and into 2012. At $36.17 its 52-week trading range is $25.78 to $57.67 and its market cap is about $5.2 billion.  Thomson Reuters has a consensus price target of $54.50, implying upside of just over 50%.  Bristol-Myers’ recent approval has helped this class of drugs which use the body’s immune system to fight cancer back in favor. Shares were around $33.00 on Friday versus $36.17 today.

Geron Corporation (NASDAQ: GERN) is the king of stem cells in America as far as the investor community is concerned.  Analysts have an average price target of $10.13 but the median target is actually $8.00.  At $4.98, this still represents about 60% implied upside to the lower target and more than 100% to an average target.  The 52-week range is $4.37 to $6.40 and its market cap is roughly $641 million.  Again, the analyst crowd is very far apart here on expectations.  Another risk to consider is that the company conducts secondary offerings on and off as it needs to raise cash to fund its expensive R&D pipeline.  This stock tends to pop around stem cell study news and presentation results being given at key conferences.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) is about six-weeks past news that it and partner Roche announced the first patient received subcutaneous MabThera (rituximab) as an anticancer biologic in a Phase 3 registration trial using Enhanze technology.  This was the second Roche cancer medicine after Herceptin to enter a Phase 3 registration study as part of the Halozyme-Roche collaboration. The clinical trial also triggered a milestone payment of $5 million to Halozyme. At $6.76 its 52-week trading range is $5.79 to $9.11 and its market cap is $685 million.  Thomson Reuters has a consensus price target of $10.80, implying upside of about 60%.  We would note that the consensus price targets are rather far apart here and no major analyst calls have been seen in some time.

VIVUS Inc. (NASDAQ: VVUS) has one of the more promising obesity drug candidates.  At $6.36 its 52-week trading range is $4.69 to $13.68 and its market cap is about $520 million. Thomson Reuters has a consensus price target of $9.36, implying upside of more than 47%. Just be advised that this ‘more promising’ notes has severe caveats.  The FDA doesn’t seem to endorse anything related to obesity treatments due to side effects and safety profiles.  The reason there is so much implied upside is because there are those who are fighting over whether or not VIVUS will win full FDA approval.

Stay tuned for another screen of other biotech-related shares in BioHealth for Thursday as there are many others with large implied upside ahead.  As always, do your own due diligence when it comes to “Wall Street Research” and always understand what you are investing in.  Speculative biotech stocks aren’t exactly for widows and orphans.

JON C. OGG

ActivIdentity Corporation (NASDAQ: ACTI) is soaring this morning after receiving a $162 million buyout offer from Assa Abloy.  Shares are up about 42.4% at $3.22 on more than 1 million shares.

Allied Irish Banks plc (NYSE: AIB) is becoming an all-too-regular character in this cast, but a movers report just about always has large moves each morning now… usually to the downside.  Shares are down 4.75% at $1.20 on over 20,000 shares.

CIENA Corporation (NASDAQ: CIEN) is trading lower after it reaffirmed guidance because it is offering $175 million in notes.  Shares are down almost 3% at $15.13 on more than 100,000 shares.

Corinthian Colleges, Inc. (NASDAQ: COCO) is lower after its President/COO resigned and no replacement was named.  Industry pressure got too much perhaps.  Shares are down 5% at $6.00 on more than 50,000 shares.

Geron Corporation (NASDAQ: GERN) is seeing continued interest after yesterday’s news of an enrollment in a stem cells study.  Shares are up 4.7% at $5.94 on almost 50,000 shares.

Interactive Intelligence (NASDAQ: ININ) was halted but the company changed its guidance:  expects to report revenues of $41 to $42 million and non-GAAP EPS of $0.35 to $0.39 and it expects 20% annual revenue growth.  Thomson Reuters has estimates of $0.23 EPS and $37.88 million.

King Pharmaceuticals Inc. (NYSE: KG) is soaring after Pfizer announced a $3.6 billion acquisition of the company for a price of $14.25 per share.  Shares are up 39% at $14.14 on more than 38 million shares.

MedQuist, Inc. (NASDAQ: MEDQ) is trading lower after a record date for its special dividend.  Shares are down 13% at $10.00 on low volume.

Synaptics Incorporated (NASDAQ: SYNA) is lower after its CEO left the company and on lower guidance.  Shares are trading lower by 6.5% at $24.14 on over 50,000 shares.

TriQuint Semiconductor, Inc. (NASDAQ: TQNT) is trading up after offering guidance this morning, a day after a downgrade on valuation concerns.  Shares are trading up 3.4% at $9.40 on more than 200,000 shares.

Tongxin International Ltd. (NASDAQ: TXIC) is trading lower after NASDAQ rejected the company’s plan and its request for continued listing on the NASDAQ Stock Market.  Shares are down almost 15% at $3.15 on about 15,000 shares.

You can join our free daily email distribution list to hear more about dividend trends, analyst upgrades and downgrades, top day trader and active trader alerts, news on Buffett and other investment gurus, IPOs, secondary offerings, private equity, and more.

JON C. OGG

Alexza Pharmaceuticals Inc. (NASDAQ: ALXA) is getting crushed after the FDA declined to approve its AZ-004 for treatment of agitation in schizophrenic or bipolar disorder patients.  This is and was its lead program.  Shares hit a new 52-week low under the prior 52-week range of $1.93 to $3.92; shares are down a whopping 52% at $1.45 and we have seen 8.3 million shares trade hands.

Alkermes, Inc. (NASDAQ: ALKS) is trading slightly lower ahead of its decision due Tuesday for the approval of its opioid addiction treatment Vivitrol.  The drug is already approved as an injection treatment for alcohol dependence and the company has already had Phase III results showing that Vivitrol helped patients against opioid addiction. A panel has already recommended approval of the drug.  Shares hit a new 52-week high again this morning of $16.03, but shares are currently down 0.9% at $15.78.

Allos Therapeutics Inc. (NASDAQ: ALTH) is down after its experimental drug called pralatrexate increased non-small cell lung cancer patients’ survival rate more than an existing treatment in a mid-stage study.  Unfortunately, the data was mixed enough that shares are down 5.7% at $4.31 in active trading.

Dendreon Corporation (NASDAQ: DNDN) is up despite potential competition.  Johnson & Johnson (NYSE: JNJ) showed that study data in men with advanced prostate cancer lived nearly four months longer on a new pill,  one which the company noted would change clinical practice.  Dendreon shares are up 3% at $40.41 on fairly active trading and its 52-week trading range is $24.79 to $57.67.

Geron Corp. (NASDAQ: GERN) is trading up after it enrolled the first patient for its early stage human-embryonic stem-cell treatment for spinal cord injuries in less than two months after the FDA removed a clinical hold.  Shares are up over 7% at $5.74 on active volume versus a 52-week range of $4.37 to $7.18.

Genzyme Corporation (NASDAQ: GENZ) is still in the mystery category.  The company’s denial of a $69 bid from Sanofi-Aventis (NYSE: SNY) was met with a final seeking of strategic alternatives to find a bidder who would pay more.  The biotech giant even went as far as to call it an opportunistic bid that is now hostile.  Shares closed at $72.75 on Friday, so it seems as though there may not be a huge hope of a competing bid that is aggressively higher than Sanofi-Aventis’ $69 offer.  Shares are trading up 0.25 at $72.92 today on hope of a higher offer.

Immunogen Inc. (NASDAQ: IMGN) is trading higher after positive cancer data and a deal with Novartis (NYSE: NVS).  Full news is at BioHealthInvestor and shares are up 5.7% at $7.71 on very active trading.

Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ) did not get a FDA nod  for its JZP-6 for fibromyalgia.  The FDA said more studies are needed,  and shares are actually up today.  In late-morning trade, shares are up 3.3% at $10.45 on active trading volume.  The 52-week range is $6.01 to $13.95.

You can join our free daily email distribution list to hear more about dividend trends, analyst upgrades and downgrades, top day trader and active trader alerts, news on Buffett and other investment gurus, IPOs, secondary offerings, private equity, and more.

JON C. OGG

Celldex Therapeutics, Inc. (NASDAQ: CLDX) is trading up 14% to $4.47 versus a 52-week range of $2.91 to $9.49 after reports that its brain cancer vaccine doubled the survival rates.  Shares were up over 20% last night and it traded over 200,000 shares after Monday’s closing bell.

Gymboree Corp. (NASDAQ: GYMB) is up 4.7% at $50.50 after hiring Goldman Sachs to find a buyer.  Keep in mind this rose 20% initially on the news Friday.

Geron Corporation (NASDAQ: GERN) is trading up ahead of a Stem Cell conference presentation and on the launch of GE Healthcare’s human cardiomyocyte product for drug discovery and toxicity screening.  Shares are up 4% at $5.38.

MEMC Electronic Materials Inc. (NYSE: WFR) is rising by about 5.6% at $12.42 after the company’s SunEdison unit announced the sale of PV factory in Italy for about $378 million.

MaxLinear, Inc. (NYSE: MXL) is trading down about 15.5% at $9.60, a 52-week low under the prior year range of $9.65 to $19.50, on news that it lowered his third quarter guidance.

SIRIUS XM Radio Inc. (NYSE: SIRI) is up again this morning with a gain of under 1% but at $1.28 which matches the 52-week high put in yesterday.  As noted at VSInvestor.com late yesterday, stock options trading is elevated and that is odd for a $1.00 stock.

The Talbots, Inc. (NYSE: TLB) is getting clipped after mixed guidance for he quarter and after setting targets out to2014.  Shares are down 10.6% at $11.21.

You can join our free daily email distribution list to hear more about dividend trends, analyst upgrades and downgrades, top day trader and active trader alerts, news on Buffett and other investment gurus, IPOs, secondary offerings, private equity, and more.

JON C. OGG

We have compiled the news or events on each company here and we have offered color and handicapping figures on each if applicable for the week ahead or for longer-term developments in each.

Activision Blizzard, Inc. (NASDAQ: ATVI) has been stuck in a dead video game sector but it may have a new catalyst.  Rumors abound that its new World of Warcraft “Cataclysm” edition will be out in early December in time for the holidays.  Whether this will happen is unknown, but that might add a nice boost to end of year sales if it occurs.  For its part, the company is keeping quiet.  Speaking of video games, Barron’s called Take-Two Interactive Software Inc. (NASDAQ: TTWO) a ‘bargain in the sagging video game sector’ and at $10.25 its 52-week range is $7.00 to $12.57.

Amazon.com Inc. (NASDAQ: AMZN) could see additional pressure as earnings season gets closer because even after a 2.1% drop to $153.71 Friday,  shares are almost 30% since before its last earnings.  A pair of analysts voiced concerns on high valuations and a 25% run in the last month.  As a reminder, Amazon.com has signaled in its prior quarter that margin issues are present and the competition for the eReader space is tight.  The 52-week trading range is $88.27 to $161.78.

Green Mountain Coffee Roasters Inc. (NASDAQ: GMCR) is about to enter its second week after disclosing its accounting issues and SEC inquiry, and the damage could have more room to come as the class action suits are starting to come up.  Shares closed down again on Friday with a 5.2% drop to $29.57.  The stock was just under $30.00 as recently as late-July and the stock was at an adjusted $23+ handle when its 3 for 1 split went into effect in May.  With a $19.87 to $37.97 range over the last year, there could still be more weakness as a bear raid continues to gain strength.  Jim Cramer also added it to the SELL BLOCK this last week.

Fidelity National Financial Inc. (NYSE: FNF) and First American Financial Corp. (NYSE: FAF) could face continued pressure as reports of bank foreclosure document errors could throw millions of property titles into question.  It will increase these firms’ operating costs to review each mortgage title and will bring down more scrutiny on their operations ahead.  FNF closed down over 4% Friday at $15.04 versus a 52-week range of $12.60 to $17.00 and FAF closed down 3.1% at $14.48 versus a 52-week range of $11.90 to $19.57.  Stewart Information Services Corp. (NYSE: STC), owner of Stewart Title, was only down 1.24% at $11.18.

• You can join our free daily email distribution list to hear more about dividend trends, analyst upgrades and downgrades, top day trader and active trader alerts, news on Buffett and other investment gurus, IPOs, secondary offerings, private equity, and more.
  
  Filed under: Banking, Business Services, Calendar, Conglomerates, Cult Stock, Earnings, Economy, Editor's Picks, Media, Rumors Tagged: AMZN, ATVI, FAF, FNF, GERN, GMCR, GYMB, JPM, MON, NBG, NFLX, SDTH, SIRI, TSLA, TTWO, UAL, UTX, WDR ]]> http://247wallst.com/2010/10/03/the-unusual-suspects-for-the-week-ahead-atvi-ttwo-amzn-gmcr-fnf-faf-gern-gymb-jpm-mon-nbg-nflx-sdth-siri-tsla-ual-utx-wdr/feed/ 0 AMZNATVIFAFFNFGERNGMCRGYMBJPMMONNBGNFLXSDTHSIRITSLATTWOUALUTXWDR Administrator bull-and-bear-image http://247wallst.com/2010/09/09/biohealth-business-daily-major-news-breaks-qcor-dndn-gern-stem-astm-cytx-nbs-btim-psti-sva-vvus-orex-arna-snts-genz-sny-teva-amgn-acor-celg-hgsi-biib-gild-exas-zgen-dyax-id/ http://247wallst.com/2010/09/09/biohealth-business-daily-major-news-breaks-qcor-dndn-gern-stem-astm-cytx-nbs-btim-psti-sva-vvus-orex-arna-snts-genz-sny-teva-amgn-acor-celg-hgsi-biib-gild-exas-zgen-dyax-id/#comments Thu, 09 Sep 2010 17:57:35 +0000 Administrator http://247wallst.com/?p=79443 ]]> Biotech and BioHealth stocks are on the move today and there is more news in the emerging sector than there has been on a single day in months and months.  The news is not even on any of the ten-bagger drug announcement tracking stocks that investors tend to fall in love with from time to time.  We have individual news and moves seen in Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Dendreon Corporation (NASDAQ: DNDN), Santarus Inc. (NASDAQ: SNTS) and Sinovac Biotech Ltd. (NASDAQ: SVA).  There is a boatload of stem cell reactions to news today; obesity drug candidate companies are all not getting an up-market memo from the stock exchanges.  We also have ongoing pending merger news and there were more drug and biotech research calls than you can easily count today.

  Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) is down over 5.5% at $9.79 after the FDA said it needed more time to review its Supplemental New Drug Application for its Acthar decision for infantile spasms.

  Dendreon Corporation (NASDAQ: DNDN) is playing a 2% game of giveback today and shares are down at $40.99.  There has been some steady hope of a deal here on and off coming down the pipe, but the Medicare review period over reimbursements (a possible price shakedown) is a steady thorn in the side of PROVENGE in the fight against prostate cancer.

  Sinovac Biotech Ltd. (NASDAQ: SVA) is trading up 7.5% at $4.30 on above average volume.  The company disclosed that there were THREE upcoming presentations:

  • Morgan Stanley Global Healthcare Unplugged Conference, New York, scheduled for September 14 at 2:10 pm ET.
  • Morgan Stanley China Global Healthcare Day, Boston, September 15 in one-on-meetings with investors.
  • UBS Global Life Sciences Conference, New York, scheduled for Monday, September 20 at 10:00 AM ET.

  Stem cells are back in vogue…. Geron Corporation (NASDAQ: GERN), StemCells Inc. (NASDAQ: STEM), Aastrom Biosciences, Inc. (NASDAQ: ASTM), Cytori Therapeutics, Inc. (NASDAQ: CYTX), Neostem, Inc. (AMEX: NBS), BioTime, Inc. (NASDAQ: BTIM) and Pluristem Therapeutics, Inc. (NASDAQ: PSTI) are all trading higher on word that US District Court has lifted that ban on federal funding for embryonic stem cells.

  VIVUS Inc. (NASDAQ: VVUS) is down 3.5% at $6.11 but it is on light trading volume.  Orexigen Therapeutics, Inc. (NASDAQ: OREX) is down 3.4% at $5.14 on thin volume, and this is the one that Takeda got on the map for a potential $1 billion obesity pill pact announced in recent weeks.  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) is also down 4% at $7.13 on fairly active trading volume.

  Santarus Inc. (NASDAQ: SNTS) is up after it secured a license for a Type II diabetes drug for the exclusive manufacturing and commercial rights to Cycloset in the U.S. with S2 Therapeutics and VeroScience.  The company will pay an upfront $5 million fee and will then pay royalties to its partners from the Cycloset sales.  Santarus shares are trading up over 14% at $2.54 on about 10-times normal trading volume.

  Genzyme Corporation (NASDAQ: GENZ) is up today on hopes of a higher Sanofi-Aventis (NYSE: SNY) bid, although this appears to be  on a false rumor.

  There was a massive push for drug and biotech research calls today.  Stocks given new coverage, upgrades, and downgrades were Teva Pharmaceutical Industries Limited (NASDAQ: TEVA), Amgen Inc. (NASDAQ: AMGN), Acorda Therapeutics, Inc. (NASDAQ: ACOR), Celgene Corporation (NASDAQ: CELG), Human Genome Sciences Inc. (NASDAQ: HGSI), Biogen Idec Inc. (NASDAQ: BIIB), Gilead Sciences Inc. (NASDAQ: GILD), EXACT Sciences Corp. (NASDAQ: EXAS), ZymoGenetics Inc. (NASDAQ: ZGEN), Dyax Corp. (NASDAQ: DYAX), IDEXX Laboratories, Inc. (NASDAQ: IDXX), and ViroPharma Inc. (NASDAQ: VPHM) all have major research calls with a FULL RESEARCH SUMMARY WITH INDIVIDUAL CALLS HERE.

  You can join our free daily email distribution list to hear more about dividend trends, analyst upgrades and downgrades, top day trader and active trader alerts, news on Buffett and other investment gurus, IPOs, secondary offerings, private equity, and more.

  JON C. OGG

  
  Filed under: Biotech, Drug companies, Pharmaceuticals, Trading Alert Tagged: ACOR, AMGN, ARNA, ASTM, BIIB, BTIM, CELG, CYTX, DNDN, DYAX, EXAS, GENZ, GERN, GILD, HGSI, IDXX, NBS, OREX, PSTI, QCOR, SNTS, SNY, STEM, SVA, TEVA, VPHM, VVUS, ZGEN ]]> http://247wallst.com/2010/09/09/biohealth-business-daily-major-news-breaks-qcor-dndn-gern-stem-astm-cytx-nbs-btim-psti-sva-vvus-orex-arna-snts-genz-sny-teva-amgn-acor-celg-hgsi-biib-gild-exas-zgen-dyax-id/feed/ 0 ACORAMGNARNAASTMBIIBBTIMCELGCYTXDNDNDYAXEXASGENZGERNGILDHGSIIDXXNBSOREXPSTIQCORSNTSSNYSTEMSVATEVAVPHMVVUSZGEN Administrator Biotech Image